Interestingly, long-term trametinib treatment (10 days) resulted in a rebound in ERK phosphorylation and further upregulation of AKT phosphorylation, suggesting rapid adaptive resistance to MEK inhibitors in KRAS-mutant lung cancer (Fig. 2a). The gene discussed is KRAS; the disease is lung carcinoma.